Form 4: Vera Therapeutics Director, Maha Katabi, Acquires 14,000 Stock Options
SEC Form 4 Filing
Director Maha Katabi acquired 14,000 stock options in Vera Therapeutics, Inc. on May 14, 2025.
Summary
- On May 14, 2025, Maha Katabi, a director of Vera Therapeutics, Inc., acquired 14,000 stock options.
- The exercise price of these options is $21.19.
- The options vest fully on the earlier of the first anniversary of the grant date or the date of the Company's 2026 annual stockholder meeting, contingent upon continuous service.
- The options also vest fully upon a change in control, subject to continuous service through that date.
- The options expire on May 13, 2035.
Sentiment
Score: 5
Explanation: The document is a neutral regulatory filing regarding stock option grants, with no inherent positive or negative sentiment.
Industry Context
This filing is a routine disclosure of stock option grants to a company director, which is a common practice in publicly traded companies to incentivize and align the interests of management with shareholders.
Key Dates
| Date | Description |
|---|---|
| 05/14/2025 | Date of transaction: Maha Katabi acquired 14,000 stock options. |
| 05/16/2025 | Date of report filing. |
| 05/13/2035 | Expiration date of the stock options. |
Keywords
stock options, Form 4, director, Vera Therapeutics, beneficial ownership, Katabi, VERA
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.